Department of Obstetrics, Gynecology & Women's Health

Phone: 502-852-5229
Email Dr. Douglas Taylor

Education:
PhD in Biochemistry, Wake Forest Univ. SoM, Winston-Salem, NC
Post-doctoral work in Immunology, Boston University School of Medicine, Boston, MA

National Positions:
2005 - NIH Study Section Member, NICHD, Perinatalogy & Neonatalogy
2005, 2006 - DoD-Congressionally Directed Medical Research Program for Ovarian Cancer - Panel Member

Honors
National Individual Research Service Award, NIH - National Cancer Institute (Tumor Immunology) - 1985
Whitaker Health Science Foundation Research Award, with Dr. S. Tonegawa - 1987 - 1989
Society for Gynecologic Investigation President's Award - 45th Annual Meeting of the SGI - 1998.
Jewish Hospital Fdn Award for Research with Major Clinical Application, with Dr. C. Gercel-Taylor - 1998.
American College of Obstetricians and Gynecologists , Searle-Donald F. Richardson Research Award - 1999.
American College of Obstetricians and Gynecologists , Searle-Donald F. Richardson Research Award  - 2002.

Recent Publications

Taylor DD, Gercel-Taylor C. Tumor-derived exosomes as mediates of T-cell signaling defects. Brit J Cancer, 92: 305-311, 2005 (Featured article).

Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. FasL+ membraneous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res, 11: 1010-1020, 2005.

Saxena A, Yashar C, Taylor DD, Gercel-Taylor C. Cellular response to chemotherapy and radiation in cervical cancer. Amer J Obstet Gynecol, 192: 1399-1403, 2005.

Yashar, C.M., Spanos, W.J., Taylor, D.D., Gercel-Taylor, C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol Oncol, 99: 199-205, 2005.

Gercel-Taylor, C., Scobee, J.J., Taylor, D.D. Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. AntiCancer Res, 25: 2113-2117, 2005.

Taylor, D.D., Akyol, S., Gercel-Taylor, C. Pregnancy-associated exosomes and their modulation of T-cell signaling. J Immunol, 176: 1534-1542, 2006.

Erkanli, A., Taylor, D.D., Dean, D., Eksir, F., Egger, D., Geyer, J., Nelson, B.H., Stone, B., Fritsche, H.A., Roden, R.B. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res, 66: 1792-1798, 2006.

Metzinger, D.S., Taylor, D.D., Gercel-Taylor, C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Letters, 236: 302-308, 2006.

Taylor, D.D., Bohler, H.C., Gercel-Taylor, C. Pregnancy-linked suppression of TcR signaling pathways by a circulating factor absent in recurrent spontaneous pregnancy loss. Mol Immunol, 43:1872-1880, 2006.

Akyol, S., Gercel-Taylor, C., Reynolds, L.C., Taylor, D.D. HSP-10 in ovarian cancer: Expression and suppression of T-cell signaling. Gynecol Oncol, 101: 581-586, 2006.

Singh, N.P., Miller, R.W., Yolcu, E.S., Kilinc, O., Oechsli, M., Huseby, R., Taylor, D.D., Perry, M.T., LaRocca, R.V., Shirwan, H. Primary Tumor Cells from Cancer Patients “Decorated” With a Novel Form of CD80 Protein Serve as Effective Antigen-Presenting Cells for the Induction of Autologous T-Cell Immune Responses Ex Vivo. Hum Gene Ther, 17:334-346, 2006.